Literature DB >> 8968085

Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

M Goggins1, M Schutte, J Lu, C A Moskaluk, C L Weinstein, G M Petersen, C J Yeo, C E Jackson, H T Lynch, R H Hruban, S E Kern.   

Abstract

Germline mutations in BRCA2 predispose carriers to the development of breast, ovarian, and a variety of other cancers. The original localization of the BRCA2 gene was aided by its homozygous deletion in a pancreatic carcinoma; indeed, an excess of pancreatic carcinoma has been seen in some BRCA2 cancer families. To determine the involvement of BRCA2 in pancreatic carcinomas, we screened for BRCA2 alterations in an unselected panel of 41 adenocarcinomas of the pancreas (30 pancreatic adenocarcinoma xenografts and 11 pancreatic cancer cell lines). Of the 15 (27%) that had allelic loss at the BRCA2 locus, 4 (9.8%) had abnormalities in the second allele upon screening of the entire BRCA2 gene by in vitro synthesized protein assay. Three of the four mutations were considered germline in origin (7.3% overall; two were confirmed in normal tissue, and one was the 6174delT mutation from the pancreatic cancer cell line CAPAN-1, for which normal tissue was unavailable). The identification of two 6174delT mutations in this series prompted us to evaluate the prevalence of this mutation in an overlapping consecutive series of 245 patients who underwent pancreatoduodenectomy for adenocarcinoma of the pancreas. Sequence analysis of this limited region of the gene identified two additional mutations: (a) one additional germline 6174delT mutation (2 of 245, 0.8% overall); and (b) a second nearby germline 6158insT mutation. One of the patients with a germline mutation had a single relative with breast cancer, and another had a single relative with prostate cancer. None had a family history of pancreatic cancer. The incidence of germline BRCA2 mutations in apparently sporadic pancreatic cancer may be at least as high as in breast or ovarian cancer. Our results suggest that some familial risks for carcinoma will be evident only through a population-based application of gene screening techniques because a low disease penetrance of the germline mutations in some families often evades clinical suspicion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968085

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  196 in total

1.  Inherited predisposition to pancreatic cancer.

Authors:  E Efthimiou; T Crnogorac-Jurcevic; N R Lemoine; T A Brentnall
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 2.  Functional domains of the BRCA1 and BRCA2 proteins.

Authors:  R Baer; W H Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-10       Impact factor: 2.673

3.  Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining.

Authors:  F Xia; D G Taghian; J S DeFrank; Z C Zeng; H Willers; G Iliakis; S N Powell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

4.  Genetic susceptibility to pancreatic cancer.

Authors:  Alison P Klein
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 5.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

6.  Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation.

Authors:  V P Yu; M Koehler; C Steinlein; M Schmid; L A Hanakahi; A J van Gool; S C West; A R Venkitaraman
Journal:  Genes Dev       Date:  2000-06-01       Impact factor: 11.361

Review 7.  Update on familial pancreatic cancer.

Authors:  H T Lynch; R E Brand; C A Deters; R M Fusaro
Journal:  Curr Gastroenterol Rep       Date:  2001-04

Review 8.  Hereditary pancreatic cancer.

Authors:  Shilpa Grover; Sapna Syngal
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

9.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

10.  High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.

Authors:  Sarah A Bannon; Maria F Montiel; Jennifer B Goldstein; Wenli Dong; Maureen E Mork; Ester Borras; Merve Hasanov; Gauri R Varadhachary; Anirban Maitra; Matthew H Katz; Lei Feng; Andrew Futreal; David R Fogelman; Eduardo Vilar; Florencia McAllister
Journal:  Cancer Prev Res (Phila)       Date:  2018-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.